Related Experiment Video
Updated: Aug 11, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment
R Kircheis1, L Wightman, M Kursa
1Boehringer Ingelheim Austria, Vienna, Austria.
Abstract:
We have developed surface-shielded ligand-polycation based gene delivery systems which are able to target gene expression to distant tumors after systemic application. Tumor-specific targeting is achieved by (1) incorporation of cell-binding ligands; and (2) shielding of the complexes from non-specific interactions with blood components and non-target cells. Shielding of polycation/DNA complexes can be achieved by coating with either polyethylene glycol or by incorporating the ligand transferrin at high densities. Following systemic application, surface-shielded DNA complexes coding for a highly active, yet highly toxic cytokine, tumor necrosis factor-alpha (TNFalpha), localized gene expression to distant tumors, resulting in hemorrhagic tumor necrosis and inhibition of tumor growth. TNFalpha activity was confined to the tumor without systemic TNF-related toxicity. These results indicate that targeted gene delivery may be an attractive strategy to use highly potent molecules in cancer treatment.
Insights
Surface-shielded gene delivery systems target distant tumors using cell-binding ligands and shielding. This approach enables localized expression of toxic tumor necrosis factor-alpha (TNFalpha), inhibiting tumor growth without systemic toxicity.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Research
Background:
- Gene therapy holds promise for cancer treatment but faces challenges in targeted delivery and systemic toxicity.
- Developing safe and effective gene delivery vehicles is crucial for localized therapeutic agent expression.
Purpose of the Study:
- To engineer surface-shielded ligand-polycation gene delivery systems for targeted gene expression in distant tumors.
- To evaluate the efficacy and safety of delivering tumor necrosis factor-alpha (TNFalpha) via these targeted systems.
Main Methods:
- Development of polycation/DNA complexes incorporating cell-binding ligands for tumor targeting.
- Shielding of complexes using polyethylene glycol or transferrin to prevent non-specific interactions.
- Systemic administration of shielded complexes encoding TNFalpha in tumor-bearing models.
Main Results:
- Targeted gene delivery localized gene expression to distant tumors.
- Systemic application of shielded complexes resulted in hemorrhagic tumor necrosis and growth inhibition.
- Therapeutic activity of TNFalpha was confined to the tumor, avoiding systemic toxicity.
Conclusions:
- Surface-shielded ligand-polycation systems offer a viable strategy for targeted gene delivery to tumors.
- This approach enables the safe use of potent cytotoxic molecules like TNFalpha for cancer therapy.
- Targeted gene delivery represents a promising avenue for developing advanced cancer treatments.
Related Concept Videos
Gene Therapy
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy

